LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Remo Panaccione  1     David T. Rubin  2     Maria T. Abreu  3     Michael Chiorean  4     Lucy Akukwe  5     Anjali Jain  5     AnnKatrin Petersen  5     Mark T. Osterman  5     Hsiuanlin Wu  5     Silvio Danese  6     Anita Afzali  7    
1 Inflammatory Bowel Disease Clinic, Calgary, Alberta, Canada
2 University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States
3 University of Miami Miller School of Medicine, Miami, United States
4 Swedish Medical Center, Seattle, United States
5 Bristol Myers Squibb, Princeton, United States
6 Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
7 Division of Digestive Diseases, University of Cincinnati, Cincinnati, United States

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing